Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Novo Nordisk (NVO 1.01%), a Danish pharmaceutical company, is the developer of Ozempic, which is often referred to as a weight-loss drug.But there is actually a nuance, albeit an important one, to ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

LONDON, May 2 (Reuters) – Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.

Ozempic-maker Novo Nordisk and the FDA are testing the seized products, according to the notice. The illegitimate products come with pen labels, cartons, fact sheets and needles that are also ...

The market value of the company surpassed the size of Denmark’s entire economy last year and, for a period, Novo Nordisk was ...

Novo Nordisk’s Wegovy is FDA-approved for weight loss, while its lower-dose GLP-1 cousin Ozempic is only officially approved for Type 2 diabetes but is often prescribed off-label for weight loss.

Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to ...